CLDI

Company Overview — What Does Calidi Biotherapeutics, Inc. Do?

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. The company's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Its pipeline of products candidates in the clinic includes NeuroNova that are allogeneic neural stem cells loaded with an oncolytic adenovirus for the treatment of high-grade gliomas; and SuperNova, which are allogeneic adipose-derived mesenchymal stem cells loaded with tumor-selective CAL1 oncolytic vaccinia virus for the treatment of advanced metastatic solid tumors. The company was founded in 2014 and is based in San Diego, California. Calidi Biotherapeutics, Inc. (CLDI) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Allan J. Camaisa and employs approximately 38 people. With a market capitalization of $2M, CLDI is one of the notable companies in the Healthcare sector.

Calidi Biotherapeutics, Inc. (CLDI) Stock Rating — Avoid (April 2026)

As of April 2026, Calidi Biotherapeutics, Inc. receives a Avoid rating with a composite score of 22.8/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.CLDI ranks #3,957 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Calidi Biotherapeutics, Inc. ranks #682 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

CLDI Stock Price and 52-Week Range

Calidi Biotherapeutics, Inc. (CLDI) currently trades at $0.26. The stock lost $0.00 (0.4%) in the most recent trading session. The 52-week high for CLDI is $7.25, which means the stock is currently trading -96.5% from its annual peak. The 52-week low is $0.20, putting the stock 26.5% above its annual trough. Recent trading volume was 469K shares, suggesting relatively thin trading activity.

Is CLDI Overvalued or Undervalued? — Valuation Analysis

Calidi Biotherapeutics, Inc. (CLDI) carries a value factor score of 6/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.70x, versus the sector average of 2.75x.

At current multiples, Calidi Biotherapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Calidi Biotherapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Calidi Biotherapeutics, Inc. (CLDI) earns a quality factor score of 12/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -560.6%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -237.9% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

CLDI Debt, Balance Sheet, and Financial Health

Calidi Biotherapeutics, Inc. has a debt-to-equity ratio of 16.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 1.59x, suggesting adequate working capital coverage. Total debt on the balance sheet is $600,000. Cash and equivalents stand at $10M.

CLDI has a beta of -0.32, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Calidi Biotherapeutics, Inc. is 27/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Calidi Biotherapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Calidi Biotherapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-5.95. Net income for the quarter was $-21M. Operating income came in at $-21M.

In FY 2025, Calidi Biotherapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-5.95. Net income for the quarter was $-20M. Operating income came in at $-20M.

In Q3 2025, Calidi Biotherapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-2.21. Net income for the quarter was $-5M. Operating income came in at $-5M.

In Q2 2025, Calidi Biotherapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-1.99. Net income for the quarter was $-6M. Operating income came in at $-6M.

Over the past 8 quarters, Calidi Biotherapeutics, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing CLDI stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

CLDI Dividend Yield and Income Analysis

Calidi Biotherapeutics, Inc. (CLDI) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

CLDI Momentum and Technical Analysis Profile

Calidi Biotherapeutics, Inc. (CLDI) has a momentum factor score of 24/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 69/100 reflects moderate short selling activity.

CLDI vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Calidi Biotherapeutics, Inc. (CLDI) ranks #682 out of 838 stocks based on the Blank Capital composite score. This places CLDI in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing CLDI against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full CLDI vs S&P 500 (SPY) comparison to assess how Calidi Biotherapeutics, Inc. stacks up against the broader market across all factor dimensions.

CLDI Next Earnings Date

No upcoming earnings date has been announced for Calidi Biotherapeutics, Inc. (CLDI) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy CLDI? — Investment Thesis Summary

The quantitative profile for Calidi Biotherapeutics, Inc. suggests caution. The quality score of 12/100 flags below-average profitability. The value score of 6/100 indicates premium valuation. Momentum is weak at 24/100, a headwind for near-term performance. High volatility (stability score 27/100) increases portfolio risk.

In summary, Calidi Biotherapeutics, Inc. (CLDI) earns a Avoid rating with a composite score of 22.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on CLDI stock.

Related Resources for CLDI Investors

Explore more research and tools: CLDI vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare CLDI head-to-head with peers: CLDI vs AZN, CLDI vs SLGL, CLDI vs VMD.